Web-Books
im Austria-Forum
Austria-Forum
Web-Books
Naturwissenschaften
Chemie
Cancer Nanotheranostics - What Have We Learnd So Far?
Seite - 3 -
  • Benutzer
  • Version
    • Vollversion
    • Textversion
  • Sprache
    • Deutsch
    • English - Englisch

Seite - 3 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Bild der Seite - 3 -

Bild der Seite - 3 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Text der Seite - 3 -

3 March 2016 | Cancer NanotheranosticsFrontiers in Chemistry biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells. Nanomaterials-based delivery systems in Theranostics (Diagnostics & Therapy) provide better penetration of therapeutic and diagnostic substances within the body at a reduced risk in comparison to conventional therapies. At the present time, there is a growing need to enhance the capability of theranostics procedures where nanomaterials-based sensors may provide for the simultaneous detection of several gene-associated conditions and nanodevices with the ability to monitor real-time drug action. These innovative multifunctional nanocarriers for cancer theranostics may allow the development of diagnostics systems such as colorimetric and immunoassays, and in therapy approaches through gene therapy, drug delivery and tumor targeting systems in cancer. Some of the thousands and thousands of published nanosystems so far will most likely revo- lutionize our understanding of biological mechanisms and push forward the clinical practice through their integration in future diagnostics platforms. Nevertheless, despite the significant efforts towards the use of nanomaterials in biologically relevant research, more in vivo studies are needed to assess the applicability of these materials as delivery agents. In fact, only a few went through feasible clinical trials. Nanomaterials have to serve as the norm rather than an exception in the future conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice of chemical modifications to incorporate into the multifunctional nanocarriers to avoid activation off-target, side effects and toxicity. Moreover the majority of studies on nano- materials do not consider the final application to guide the design of nanomaterial. Instead, the focus is predominantly on engineering materials with specific physical or chemical properties. It is imperative to learn how advances in nanosystem’s capabilities are being used to identify new diagnostic and therapy tools driving the development of personalized medicine in oncol- ogy; discover how integrating cancer research and nanotechnology modeling can help patient diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on current research efforts; and last but not least, learn what approaches are proving fruitful in turning promising clinical data into treatment realities. Citation: Conde, J., Baptista, P. V., Fuente, J. M. D. L., Tian, F., eds. (2016). Cancer Nanotheranos- tics: What Have We Learned So Far? Lausanne: Frontiers Media. doi: 10.3389/978-2-88919-776-7
zurück zum  Buch Cancer Nanotheranostics - What Have We Learnd So Far?"
Cancer Nanotheranostics What Have We Learnd So Far?
Titel
Cancer Nanotheranostics
Untertitel
What Have We Learnd So Far?
Autoren
João Conde
Pedro Viana Baptista
Jesús M. De La Fuente
Furong Tian
Herausgeber
Frontiers in Chemistry
Datum
2016
Sprache
englisch
Lizenz
CC BY 4.0
ISBN
978-2-88919-776-7
Abmessungen
21.0 x 27.7 cm
Seiten
132
Schlagwörter
Nanomedicine, Nanoparticles, nanomaterials, Cancer, heranostics, Immunotherapy, bioimaging, Drug delivery, Gene Therapy, Phototherapy
Kategorien
Naturwissenschaften Chemie
Web-Books
Bibliothek
Datenschutz
Impressum
Austria-Forum
Austria-Forum
Web-Books
Cancer Nanotheranostics